

# NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

## HEALTH TECHNOLOGY APPRAISAL PROGRAMME

### Equality impact assessment – Guidance development

#### STA Prucalopride for the treatment of chronic constipation in women

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

#### Consultation

1. Have the potential equality issues identified during the scoping process been addressed by the Committee, and, if so, how?

The consultees discussed equality implications relating to the fact that prucalopride is likely to only be licensed for women. It was noted that any guidance produced by NICE for prucalopride will be dictated by prucalopride's final marketing authorisation. In light of this, it was agreed that no changes to the draft scope relating to equalities issues were required.

2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the Committee addressed these?

The manufacturer noted in its submission that the marketing authorisation restricts the use of prucalopride to women and that this may appear to discriminate against men. This issue was also noted by a comparator manufacturer (Norgine) in its response to the draft scope. The Committee noted that the burden of chronic constipation is two to three times more common in women than men, but considered that this was not an equality issue because any guidance produced by NICE for prucalopride will be in line with its marketing authorisation, which targets use to women only. The manufacturer stated that at some time in the future the indication may be extended to include men with chronic constipation who fail to achieve adequate relief with laxatives.

3. Have any other potential equality issues been identified by the Committee, and, if so, how has the Committee addressed these?

No additional equality issues were raised by Committee.

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to access for the specific group?

No barriers to the access of prucalopride were considered to result from the preliminary recommendations.

5. Are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to access identified in question 4, or otherwise fulfil NICE's obligations to promote equality?

N/A

6. Have the Committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?

The summary table in the ACD states that no equality issues were raised during the scoping exercise or through the course of this appraisal.

**Approved by Associate Director (name): Elisabeth George**

**Date:** 13 12 10 (the new EIA procedure not implemented at the time of ACD meeting)

### **Final appraisal determination**

1. Have any additional potential equality issues been raised during the

consultation, and, if so, how has the Committee addressed these?

No equality issues were raised during consultation.

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to access for the specific group?

No barriers to the access of prucalopride were considered to result from the final recommendations.

3. If the recommendations have changed after consultation, are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to access identified in question 2, or otherwise fulfil NICE's obligations to promote equality?

N/A

4. Have the Committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

The summary table in the FAD states that no equality issues were raised during the scoping exercise or through the course of this appraisal.

**Approved by Centre or Programme Director (name):** Meindert Boysen

**Date:** 13/12/2010